anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cosmetic use of a substance for inhibiting non-pathological DNA methylation for stimulating the formation of elastic fibers in order to reduce skin wrinkles, to fight against sagging tissue especially when the tissue relaxation is observed during aging or sun exposure, to densify the extracellular matrix, to strengthen a subcutaneous tissue, to exert an anti-wrinkle effect, or to fight against stretch marks, is claimed. An independent claim is included for a substance for inhibiting the methylation of DNA to stimulate the elastic fiber formation. ACTIVITY : Vulnerary; Dermatological. MECHANISM OF ACTION : DNA-methyltransferase 3A (DNMT3a) inhibitor. The DNMT3a inhibitory activity of the substance for inhibiting non-pathological DNA methylation was tested in a human embryonic kidney 293 cell. The result showed that the inhibition activity of substance was 68%.
KIDCOV is a longitudinal cohort study that will prospectively follow cohorts of COVID19-negative and COVID19-positive adults for episodes of kidney injury over a 12-months period. Study candidates will be identified via site-specific electronic medical records (EMR) at seven academic medical centers in the U.S. within 4 weeks of a PCR-based test for SARS-Cov2. Screen-positive individuals will be contacted by email or text and invited to complete an online consent form documenting their willingness to participate. Participation will involve completion of questionnaires and return of urine samples in mailed collection kits at 2, 6, and 12 months after their date of PCR test. The primary endpoint will be the urine-based KIT Score, based on the composite measurement of multiple DNA, protein and metabolite urinary biomarkers (reference). Secondary endpoints include NGAL and KIM-1 urinary biomarkers for kidney injury assessment.

Early detection of new or worsening kidney injury is urgently needed in order to implement preventative measures and target therapeutics that can minimize excess post-COVID19 kidney damage. A complete and standardized understanding of the trajectory and risk factors for kidney injury associated with COVID19+ disease is critical to informing the design and implementation of preventative and therapeutic strategies for COVID19-mediated kidney injury.
Breast cancer is the most common cancer in women, and up to 70% of breast cancer patients are positive for hormone receptors. Most of them are estrogen receptor (ER) positive, and more than 95% of progesterone receptor (PR) positive tumors are also ER positive. The staging system most commonly used for BC is the American Joint Committee on Cancer TNM system, which is based on seven criteria - tumor extent (T), spread to nearby lymph nodes (N), spread (metastasis) to distant sites (M), cancer grade ( G), estrogen receptor (ER) status, progesterone receptor status (PR) and HER2/neu . Breast cancer is characterized by different pathological features, different responses to treatment, and significant differences in long-term survival among patients . In general, the molecular typing of breast cancer is mainly divided into four types: the first, luminalA type refers to ER, PR positive, HER2 negative, and endocrine therapy can be performed. The second, luminalB type means that ER, PR and HER2 are all positive, endocrine therapy, chemotherapy and targeted therapy can be used, and the therapeutic effect is relatively good. The third type, HER2 overexpression type is HER2 positive, ER and PR are both negative, this type is ineffective for endocrine therapy, and targeted therapy can be used. Fourth, ER, PR and HER2 are all negative , and the treatment effect is the worst. In general, the two subtypes of luminalA and B have higher long-term survival rates. Meanwhile,HER2 overexpression and triple-negative breast cancer have a poor prognosis.

The success of breast cancer treatment depends heavily on tumor estrogen receptor status, which is currently assessed by immunohistochemistry. While immunohistochemistry is well suited to detect primary breast tumors, metastatic foci are less accurate. Estrogen receptor expression changes over time, and inconsistent expression between primary and metastatic tumors has been observed in up to 40% of patients.Studies have shown the potential role of FES-PET/CT in assessing ER status, especially in patients with multiple tumors or that are difficult to biopsy.FES-PET/CT as an imaging technique targeting estrogen receptors may help predict patient response to endocrine therapy. Therefore, FES PET/CT imaging is of great significance for the selection of patients who benefit from endocrine therapy and those who are better through adjuvant chemotherapy .
Nonalcoholic fatty liver disease (NAFLD) includes simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and eventually cirrhosis and hepatocellular carcinoma (HCC). The diagnosis of NAFLD is based on the detection of excess fat disposition in the liver, which is the first step to trigger further evaluation of NAFLD, including necroinflammation and fibrosis. In this review, we discuss non-invasive biomarkers and imaging tools that are currently and potentially available for different features (steatosis, necroinflammation and fibrosis) and disease severity assessment of NAFLD. In the past 2 decades, advances in non-invasive tests of fibrosis have transformed the management of NAFLD. Blood and imaging biomarkers have already been evaluated in multiple studies for the diagnosis of fibrosis and cirrhosis. Among the various histological features of NAFLD, the degree of fibrosis has the strongest correlation with liver-related morbidity and mortality. Non-invasive tests of fibrosis have been shown to predict liver-related outcomes, both in the general population and among patients with NAFLD. What is lacking, however, is good data to support the use of non-invasive tests as monitoring and response biomarkers. With the conclusion of several large phase 3 studies in the next few years, the availability of paired liver biopsy, non-invasive test and clinical outcome data will likely advance the field and shed light on new biomarkers and the way to use various non-invasive tests in a longitudinal manner.
1,157,947. Streptococcus hemolyticus of high anti-tumour activity. CHUGAI SEIYAKU K.K. Oct. 30, 1967 [Oct. 31, 1966], No.49275/67. Heading C6F. A process for obtaining cells of hemolytic Streptococci having high anti-tumour activity involves cultivating hemolytic Streptococci having anti-tumour activity, particularly Streptococcus hemolyticus ATCC No. 21060, in a culture medium containing a yeast extract, and separating bacterial cells from the cultivated broth. The yeast extracted may be obtained by dissolving a commerically available yeast extract or auto-lysate in water, neutralizing and heating the solution, and then taking away the insoluble fraction by filtering. The culture medium of pH 7À0-7À4 typically contains between 3 and 6 grams per decilitre of yeast extract and such other constituents as peptone, fish meat extract, beef extract, horse or whale flesh extract, ribonucleic acid and/or its ribonuclease core, sodium chloride, sodium hydrogen phosphate and sodium hydrogen carbonate. The hemolytic Streptococci may be preliminarily cultivated in a yeast extract medium or beef infusion medium at 37‹ C. for 24 hours. The main cultivation is then carried out at 37‹ C. for periods ranging from 10 to 30 hours (according to circumstances). The separated cells are suspended in a medium containing penicillin and heated at 30-38‹ C. for 10-30 minutes and then at 40-50‹ C. for 20-40 minutes to eliminate their virulence and hemolysin-producing activity. A suitable suspension medium (Bernheimer's Basal Medium) is composed of (a) 6 ml. of a solution consisting of 675 mg. of maltose and an aqueous solution containing 20 grams 1 decilitre of potassium dihydrogen phosphate, adjusted to pH 6À9-7À0 with sodium hydroxide, (b) 12 ml. of an aqueous solution containing 2 grams 1 decilitre of magnesium sulphate heptahydrate and (c) 66 ml. of distilled water.
Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
This invention describes unique treatment methods and innovative articles that can be placed in a human or animal body to enable controlled destruction of diseased tissue. The methods include destruction of diseased cells and tissues by magnetically controlled motion and an externally controllable drug delivery process with a capability to start and stop the drug delivery at any time, for any duration. This invention provides two approaches to diseased cell destruction, (1) magneto-mechanical disturbance of cell structure (e.g. cancer cells) for cell lysis and (2) magnetically activated drug release at local regions (e.g. tumors) from a magnetic-particle-containing drug reservoir. The invention also provides combinations of both the above treatments for dual therapy. It further combines one or both of the treatments with magnetic hyperthermia for multifunctional cell destruction therapy. The approaches can be combined with magnetic MRI for monitoring the accuracy of placement as well as for following up the cancer destruction progress and appropriate reprogramming of the magneto-mechanical therapy and remote-controlled drug release.
A multidisciplinary team composed of a pharmacist, social worker, community health worker, and dietician will provide glucose monitoring, medication titration, diet education and reinforcement, and referrals for social needs. The pharmacist will remind patients to get A1C readings at 3 months and 6 months. The team will interact with the patients predominantly via tele-health remotely for 6 months.
Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
Genome-wide association studies (GWAS) have identified >80 Alzheimer's disease and related dementias (ADRD)-associated genetic loci. However, the clinical outcomes used in most previous studies belie the complex nature of underlying neuropathologies. Here we performed GWAS on 11 ADRD-related neuropathology endophenotypes with participants drawn from the following three sources: the National Alzheimer's Coordinating Center, the Religious Orders Study and Rush Memory and Aging Project, and the Adult Changes in Thought study (n = 7,804 total autopsied participants). We identified eight independent significantly associated loci, of which four were new (COL4A1, PIK3R5, LZTS1 and APOC2). Separately testing known ADRD loci, 19 loci were significantly associated with at least one neuropathology after false-discovery rate adjustment. Genetic colocalization analyses identified pleiotropic effects and quantitative trait loci. Methylation in the cerebral cortex at two sites near APOC2 was associated with cerebral amyloid angiopathy. Studies that include neuropathology endophenotypes are an important step in understanding the mechanisms underlying genetic ADRD risk.
PROBLEM TO BE SOLVED: To obtain a keratotic plug remover which keeps high film strength even under high humidity and can certainly remove keratotic plug clogging pores in the skin by including a copolymer containing a vinyl monomer bearing salt-forming groups and a hydrophobic vinyl monomer as essential monomers. SOLUTION: This keratotic plug remover is obtained by including a copolymer, which contains at least (A) vinyl monomer [e.g. maleic acid, dimethylaminoethyl (meth)acrylate or the like] bearing salt-forming groups (e.g. carboxyl, acid anhydride, phosphonic acid and the like) and (B) hydrophobic vinyl monomer, e.g. an alkyl (meth)acrylate, an alkyl (meth)acrylamide or the like as essential monomers, as an active ingredient. The components A and B are preferably blended in proportions of 20-95 mol% and 5-80 mol%, respectively, based on the whole monomer used in the above copolymerization. Further, the above copolymerization can be carried out by all means of bulk polymerization, solution polymerization, suspension polymerization, emulsion polymerization and the like in the presence of a radical polymerization initiator.
Patients will watch a VR-360 distraction video during dressing change. The patient will be asked or helped to wear the HMD write in full at the onset of a procedure and watch the VR-360 video during the dressing change procedure. When experiencing pain, the patient may indicate the need for further analgesic medication during the procedure, the patient will be asked to push a button in their hand that will trigger a light-based signal for the nurse to provide further analgesic medication. Should their hands both be involved in the burn injury, the patient will indicate the same verbally.
<P>PROBLEM TO BE SOLVED: To display on a cellular phone a current disease name, a medication, and the like of a registered user who gets worse in his/her physical condition, only by making a call from the cellular phone.  <P>SOLUTION: A medical information server system 10 stores a user database. In the user database, there is registered user medical information including the present disease name and the medicine name under medication of the registered user in association with the telephone number, e-mail address, or the like of the cellular phone of the registered user. When the server system 10 receives a call, the server system 10 acquires the telephone number of the cellular phone by which the call is given, and detects whether the acquired telephone number is included in the user database. If the telephone number is included, the server system 10 reads the user medical information associated with the telephone number, and also generates e-mail including the read user medical information, and then transmits it to the cellular phone of the registered user.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE: A composition for treating dermatitis containing Lithospermum erythrorhizon Sieb et Zucc. extract is provided to moisturize to dry skin and maximize wound healing effect. CONSTITUTION: A composition for treating dermatitis contains 0.001-0.1 mg/ml of Lithospermum erythrorhizon Sieb et Zucc. extract. The Lithospermum erythrorhizon Sieb et Zucc. extract is hot water extract. A method for producing the Lithospermum erythrorhizon Sieb et Zucc. extract comprises: a step of adding 500ml of distilled water to 100g of Lithospermum erythrorhizon Sieb et Zucc. and heating for three hours; a step of filtering the extract and freeze-drying.
* Use Oxycodone HCl Controlled-Release Tablets the way your doctor tells you to.
  * Use Oxycodone HCl Controlled-Release Tablets only for the condition for which it was prescribed.
  * Oxycodone HCl Controlled-Release Tablets are not for occasional (“as needed”) use.
  * Swallow the tablets whole. Do not break, crush, dissolve, or chew them before swallowing. Oxycodone HCl Controlled-Release Tablets work properly over 12 hours only when swallowed whole. If a tablet is broken, crushed, dissolved, or chewed, the entire 12 hour dose will be absorbed into your body all at once. This can be dangerous, causing an overdose, and possibly death.
  * Keep Oxycodone HCl Controlled-Release Tablets out of the reach of children. Accidental overdose by a child is dangerous and may result in death.
  * Prevent theft and misuse. Oxycodone HCl Controlled-Release Tablets contain a narcotic painkiller that can be a target for people who abuse prescription medicines. Therefore, keep your tablets in a secure place, to protect them from theft. Never give them to anyone else. Selling or giving away this medicine is dangerous and against the law.
PURPOSE:To obtain a lithium salt which is a lithium salt of a taste-relating substance, 5'-inosinic acid, has hypotensive action of high safety with reduced side effect and can be used as an effective hypotensor in the forms of oral, injection and drip phleboclytic preparations. CONSTITUTION:Triethyl phosphate is allowed to react with phosphorus oxychloride under stirring, the reaction mixture is cooled down to 5 deg.C and dripped in water, then inosinic acid is added to effect phosphorylation. The reaction mixture is poured in water at 0 deg.C to continue the reaction at 5 deg.C for 1 hour, then extracted with toluene. Then, the solvent is removed from the extract to collect the residue. The residue is passed through the activated carbon column treated with lithium hydroxide and hydrochloric acid, eluted with 3.5% lithium hydroxide, the eluate is concentrated at 60 deg.C, then cooled down to 25 deg.C to precipitate crystals whereby new lithium 5'-inosinate is obtained. The compound is formulated with alpha-form starch, corn starch and magnesium stearate into a hypotensive preparation of low toxicity with no side effect.
In-vehicle user health platform systems and methods are disclosed. The in-vehicle health platform system can include a display within a vehicle and a computer coupled to the display. The display can be on a dashboard of the vehicle or display computer having a plurality of display areas. The computer can receive health data for a user and provide options for the user to select a type of health data and report to display in one or more display areas of the display based on the received health data. The health data can include at least one of sleep data, vital signs data, oxygen level data, and workout data of the user. The health data can be received from at least one of a wearable, a health measuring device, and a weight measuring device within the vehicle. The health platform system can provide options including a sleep option to display or report the sleep data, vital signs option to display or report the vital signs data, oxygen level option to display or report the oxygen level data, and workout option to display or report the workout data. The computer can display or report the health data by displaying patterns of the health data for the user related to at least one of the sleep option, vital signs option, oxygen level option and workout option in one or more display areas of the display. The patterns can include one or more graphical elements shown on the display. The computer can provide user advice or tips to improve fitness or well-being in one or more display areas of the display based on the patterns of the health data. The advice or tips can include activity suggestions to achieve health or fitness goals or health measurement levels for the user.
FIELD: medicine, pharmacy, vaccines. SUBSTANCE: invention relates to production of antiviral vaccine preparations in tabletted form. Method involves measles virus multiplication on cellular substrate, collection of virus-containing fluid, cellular detritis removal and addition of stabilizing composition followed by lyophilization of a preparation. Virus-containing fluid is collected at virus titer 5.0-6.0 lg TCD (toxic cytopathic dose) 50/0.5 ml and at protein content 16 mcg/ml, not above. Sucrose, gelatose and peptone are added to virus-containing fluid as a stabilizing composition up to their final concentration in mixture by 3 wt.-% for each component. After lyophilization a dried virus-containing material is milled, mixed with lactose and calcium stearate at the following ratio of components, wt.-%: lyophilized virus-containing material at activity 4.5 lg TCD 50/0.5 ml, not less 49-98; lactose 0.1-49, and calcium stearate 1.5-2.5. Obtained mass is tabletted and tablets are covered with acid-resistant shell based on acetylphthalylcellulose. Prepared live antimeasles vaccine in tabletted form can be used for oral using. EFFECT: improved method of vaccine preparing, simple and economical equipment.
PTCL patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1, ipilimumab IV over 30 minutes on day -3 and cemiplimab IV over 30 minutes on day -3 in the absence of disease progression or unacceptable toxicity. Patients undergo SPECT, CT scan, PET scan throughout the study. Patients may undergo tumor biopsy, bone marrow biopsy and blood sample collection throughout the study.
Chronic endometritis (CE) is a persistent in endometrium that is characterized by the presence of plasma cells. Recently, there has been increasing interest in the role of CE in recurrent pregnancy loss (RPL). One of the most common uterine abnormalities for RPL is Intrauterine adhesion (IUA).Intrauterine adhesion, also known as Asherman's syndrome, is the partial or complete occlusion of the uterine cavity as a result of endometrium damage. Most intrauterine adhesions patients manifest amenorrhea, reduced menstrual pattern, infertility, and intrauterine growth restriction, which seriously affect their reproductive health.It is well established that the formation of IUA likely involves hypoxia, reduced neovascularization, and altered expression of adhesion-associated cytokines, but the exact mechanisms are not well understood. Although excessive curettage is considered the primary cause, intrauterine adhesion is known to be associated with diverse non-traumatic factors, such as postabortal sepsis, puerperal sepsis and infections. It is therefore possible to hypothesize that Intrauterine adhesion may be related to chronic endometritis. To the best of researchers knowledge,there have been no reports investigating this relationship. The aim of this study was to clarify the hypothesis by evaluating the prevalence of chronic endometritis (CE) in women with severe intrauterine adhesions and compare recurrence of adhesion in women with and without chronic endometritis (CE).
Patient medical information is processed for storage and retrieval subject to anonymity constraints. The patient medical information is divided into a first information portion including information identifying a patient and information identifying a physician of the patient, and a second information portion including clinical and demographic information for the patient and the information identifying the physician. A unique code associated with the patient, but which does not identify the patient, is obtained when the first and second information portions are processed. The unique code is appended to the first and second information portions. The first information portion is then stored in a first information storage facility with other first information portions for other patients, and the second information portion is stored in a second information storage facility, separate from the first information storage facility, with second information portions for other patients. The anonymity constraints include the ability to mine the second information storage facility for clinical and demographic information useful for evaluating protocols for clinical trials and assembling candidate groups for the clinical trials without revealing the identities of the patients. Search results are made available to physicians who are identified in the results. Those physicians may then recruit their patients for participation in clinical trials.